Li A.-N.,The First Laboratory of Lanzhou Institute of Biological Products Co. |
Hu H.,The First Laboratory of Lanzhou Institute of Biological Products Co. |
Zhu Y.-Z.,The First Laboratory of Lanzhou Institute of Biological Products Co. |
Luo S.-Q.,The First Laboratory of Lanzhou Institute of Biological Products Co. |
And 6 more authors.
Chinese Journal of New Drugs | Year: 2016
Objective: To develop a nuclear magnetic resonance (NMR) method for analysis of residual pyridine borane (Py-BH3) content in pneumococcal polysaccharide derivatives. Methods: The pulse program was zgpr (water suppression experiment).1H-NMR spectra were collected at 298 K with a 7 211 Hz spectral width, 2.272 s acquisition time and 2 s relaxation delay, accumulating 512 scans. The spectra were weighted with 1.0 Hz line broadening and Fourier transformed. For data acquisition and processing, Topspin version 3.0 software was used. The method was developed and verified for specificity, detection limit and robustness. Results: Using the developed method, the solvent for determination of residual Py-BH3 content showed no interference to the component to be tested. Py-BH3 and pneumococcal polysaccharide derivatives showed distinguished characteristic peaks by NMR detection, and the peaks were completely separated after the test substances were mixed together, indicating high specificity. Py-BH3 signals could be detected clearly within the Py-BH3 concentration of 1%~0.01%, and good signal-noise ratio (S/N) was obtained. The limit of detection was 0.02%. Chemical shift and S/N did not change significantly when test temperature was changed, indicating good robustness. Conclusion: The developed NMR method shows high specificity and robustness for detection of residual Py-BH3 content in pneumococcal polysaccharide derivatives, which is suitable for the test of pneumococcal conjugate vaccine. © 2016, Chinese Journal of New Drugs Co. Ltd. All right reserved.
Shi Z.,Sichuan University |
Shi Z.,Guizhou Normal University |
An N.,Sichuan University |
Lu B.M.,Sichuan University |
And 8 more authors.
Cell Proliferation | Year: 2014
Objectives: Protein kinases orchestrate activation of signalling cascades in response to extra- and intracellular stimuli for regulation of cell proliferation. They are directly involved in a variety of diseases, particularly cancers. Systems biology approaches have become increasingly important in understanding regulatory frameworks in cancer, and thus may facilitate future anti-cancer discoveries. Moreover, it has been suggested and confirmed that high-throughput virtual screening provides a novel, effective way to reveal small molecule protein kinase inhibitors. Accordingly, we aimed to identify kinase targets and novel kinase inhibitors. Materials and methods: A series of bioinformatics methods, such as network construction, molecular docking and microarray analyses were performed. Results: In this study, we computationally constructed the appropriate global human protein-protein interaction network with data from online databases, and then modified it into a kinase-related apoptotic protein-protein interaction network. Subsequently, we identified several kinases as potential drug targets according to their differential expression observed by microarray analyses. Then, we predicted relevant microRNAs, which could target the above-mentioned kinases. Ultimately, we virtually screened a number of small molecule natural products from Traditional Chinese Medicine (TCM)@Taiwan database and identified a number of compounds that are able to target polo-like kinase 1, cyclin-dependent kinase 1 and cyclin-dependent kinase 2 in HeLa cervical carcinoma cells. Conclusions: Taken together, all these findings might hopefully facilitate discovery of new kinase inhibitors that could be promising candidates for anti-cancer drug development. © 2014 John Wiley & Sons Ltd.
Liu X.-Q.,China National Biotec Group Company Ltd |
Ma Y.-L.,China National Biotec Group Company Ltd |
Yang Z.-N.,China National Biotec Group Company Ltd |
Zhang M.,China National Biotec Group Company Ltd |
And 3 more authors.
Chinese Journal of Biologicals | Year: 2015
Objective: To evaluate the safety of influenza vaecinetsplit virion) manufactured by Beijing Tiantan Biological Products Co., Ltd, in population at ages of more than 60 years during 2011 ∼ 2012 in Beijing City. Methods: The data on adverse events following immunization (AEFIs) cases in people at ages of more than 60 years in Beijing City during 2011 to 2012, after free vaccination with influenza vaccine (split virion), were collected by AEFI information system, and analyzed by descriptive methodology. Results: Of the 536 812 recipients of vaccine manufactured by Beijing Tiantan Biological Products Co., Ltd, 10 cases of AEFIs were reported, including 6 cases of adverse reactions (3 cases of general reactions and 3 cases of abnormal reactions), indicating an incidence of adverse reactions of 1. 12/100 000. However, of the 701 820 recipients of vaccines by other manufacturers, 21 cases of AEFIs were reported, including 10 cases of adverse reactions (6 cases of general reactions and 4 cases of abnormal reactions), indicating an incidence of adverse reactions of 1. 42/100 000. No significant differences were observed in reported incidences of total adverse reactions, general reactions and abnormal reactions (P> 0. 05). Conclusion: The influenza vaccine (split virion) manufactured by Beijing Tiantan Biological Products Co., Ltd showed high safety, which might be used for the prevention of influenza in the relevant population.